HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

CNTO 736

synthetic GLP-1 receptor agonist constructed from a GLP-1 peptide analog, a VH domain, and CH2 and CH3 domains of an Fc; affects insulin resistance and inhibits VLDL production
Also Known As:
CNTO-736; CNTO736
Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ort, Tatiana: 2 articles (01/2009 - 07/2008)
2. Stojanovic-Susulic, Vedrana: 2 articles (01/2009 - 07/2008)
3. Havekes, Louis M: 1 article (01/2009)
4. Parlevliet, Edwin T: 1 article (01/2009)
5. Romijn, Johannes A: 1 article (01/2009)
6. Corssmit, Eleonora P M: 1 article (01/2009)
7. O'Neil, Karyn: 1 article (01/2009)
8. Picha, Kristen: 1 article (01/2009)
9. Pijl, Hanno: 1 article (01/2009)
10. Schröder-van der Elst, Janny P: 1 article (01/2009)

Related Diseases

1. Insulin Resistance
2. Body Weight (Weight, Body)

Related Drugs and Biologics

1. Lipoproteins (Lipoprotein)
2. glucagon-like peptide receptor (receptor, glucagon-like peptide)
3. Glucose (Dextrose)